Abstract
BACKGROUND Bcl-2 gene is an apoptotic protein that blocks apoptosis and thereby its over expression contributes to neoplastic transformation and decreased tumour survival. So, it is necessary to find out the relationship of Bcl-2 expression with histological types and tumour grade in ovarian surface epithelial tumours, which may predict the prognosis. METHODS The objective was to study the expression of Bcl-2 in ovarian surface epithelial tumours and to correlate Bcl-2 expression with histopathological features and tumour grade in ovarian surface epithelial tumours. Histological types and tumour differentiation for each case is determined from the routine H and E sections. Immunohistochemical stain for Bcl-2 was done. Then intensity and extent of staining for Bcl-2 was compared with the age, histological type and tumour grade. RESULTS Out of the 47 cases studied, 66% were in <55 years of age category and 34% in >55 years of age group. There was statistically significant associations of Bcl-2 expression with various histological types (P<0.001) and tumour differentiation (P<0.001). In the case of extent of Bcl-2 staining, statistically significant associations were present with various histological types (P=0.004) and tumour differentiation (P<0.001). CONCLUSIONS Bcl-2 expression decreases with tumour progression. Poorly differentiated tumours with decreased Bcl-2 expression may be helpful in predicting disease progression. Further studies are warranted since, Bcl-2 expression may be important for prognostic outcome or provide useful targets for therapeutic intervention in patients with surface epithelial ovarian cancers. KEY WORDS Bcl-2, Immunohistochemistry, Tumour Grade, Epithelial Tumours.
Publisher
Akshantala Enterprises Private Limited
Reference19 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018
2. [2] Danforth KN, Im TM, Whitlock EP. Addendum to screening for ovarian cancer: evidence update for the US preventive services task force reaffirmation recommendation statement. AHRQ Publication No. 12-05165-EF4. Rockville, MD: Agency for Healthcare Research and Quality April 2012.
3. Hallmarks of cancer: the next generation;Hanahan;Cell,2011
4. The Bcl2 family: regulators of the cellular life-or-death switch;Cory;Nat Rev Cancer,2002
5. The prognostic importance of p53, Bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy;Skirnisdottir;Int J Gynecol Cancer,2002